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Abstract: Crude ethyl acetate extract of Gerbera piloselloides (L.) Cass. was investigated by dual
high-resolution PTP1B/α-glucosidase inhibition profiling and LC-PDA-HRMS. This indicated the
presence of a series of unprecedented prenyl- and geranyl-substituted coumarin derivatives correlated
with both α-glucosidase and PTP1B inhibitory activity. Repeated chromatographic separation
targeting these compounds led to the isolation of 13 new compounds, of which ten could be
isolated as both enantiomers after chiral separation. The structures of all isolated compounds were
characterized by HRMS and extensive 1D and 2D NMR analysis. The absolute configurations of
the isolated compounds were determined by comparison of experimental and calculated electronic
circular dichroism spectra. Compound 6 features a rare furan-oxepane 5/7 ring system, possibly
formed through addition of a geranyl unit to C-3 of 5-methylcoumarin, representing a new type
of geranyl-substituted coumarin skeleton. Compounds 19 and 24 are the first examples of dimeric
natural products consisting of both coumarin and chromone moieties.
Keywords: Gerbera piloselloides; coumaroyl derivative; protein-tyrosine phosphatase 1B;α-glucosidase;
chiral separation; electronic circular dichroism; X-ray
1. Introduction
Diabetes mellitus is a multifactorial disease characterized by insufficient regulation of glucose
metabolism, with severe long-term micro- and macrovascular complications such as retinopathy,
neuropathy, nephropathy and cardiovascular diseases. More than 463 million people were affected
by diabetes worldwide in 2019, and this figure is estimated to increase to 700 million by 2045 [1].
Type 2 diabetes (T2D) comprises more than 90% of all diabetes cases and is characterized by decreased
insulin sensitivity in target organs like muscle and adipose tissue as well as reduced pancreatic insulin
secretion [2,3]. Thus, management of a relatively stable blood glucose in the interval 5–10 mmol/L
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by hypoglycemic drugs is of utmost importance for diabetics. One target for management of T2D
is protein tyrosine phosphatase 1B (PTP1B) [4,5], which acts as a negative modulator of insulin by
dephosphorylation of the insulin receptor and the insulin receptor substrate. α-Glucosidase constitutes
another potential T2D target enzyme [6]. It is found in the brush border of the small intestines, where
it hydrolyses terminal non-reducing 1,4-linked α-glucose residues to absorbable monosaccharides for
managing a low and stable blood glucose level. There are still no clinically approved PTP1B inhibitors
for diabetics, and the clinically approved drugs acarbose, miglitol and voglibose are associated with
side effects such as flatulence, diarrhea and stomach ache [7]. Thus, there is an unmet need for new
PTP1B and α-glucosidase inhibitors as potential T2D drug leads.
Gerbera piloselloides (L.) Cass. (Compositae) is a perennial herb commonly found in southwest
China. It is mentioned in local traditional medicine books, where it is recommended as a remedy for
treating fever, cough, and snake bites [8]. Previous studies have shown that Gerbera spp. are rich in
coumarins [9–16], with substituents regularly occurring at C-3 and C-4 of the α-pyrone moiety, as seen
for dibothrioclinin I and II [11], gerdelavin A [12], and gerberlin A-C [13]. Coumarins from Gerbera
have been reported to possess anticancer [13–15], antioxidant [16], antimicrobial [15], anti-HIV [17],
and hypoglycemic activity [18]. However, to date only a few studies of the phytochemistry and the
pharmacological activity of G. piloselloides and its constituents have been published [11,16,19], and this
species therefore holds promise for discovery of new natural products with pharmacological activity.
The ability to pinpoint the constituent(s) correlated with one or more bioactivities in a complex
extract can significantly speed up the identification of bioactive natural products. One way of
achieving this is by microfractionation of the eluate from analytical-scale HPLC separation of crude
extracts followed by assaying of the material in each well with selected assay(s). The results
expressed as percentage inhibition are then plotted at their respective retention time to provide a
high-resolution inhibition profile (biochromatogram) with a typical resolution of 4 to 10 datapoints per
min. The biochromatogram can be represented underneath the chromatographic traces, which allows
direct pinpointing of HPLC peaks correlated with peaks in the biochromatogram. This approach
has been successfully used to accelerate identification of α-glucosidase [20], α-amylase [21], aldose
reductase [22], and PTP1B [23] inhibitors as well as radical scavengers [24], using either single [25],
dual [26], triple [22], or quadruple [27] high-resolution inhibition profiling.
Here, we report the combined use of LC-PDA-HRMS and dual high-resolution PTP1B/α-glucosidase
inhibition profiling, that for the first time directly pinpoints α-glucosidase and PTP1B inhibitors in G.
piloselloides. This was used to guide isolation towards a series of unusual prenyl- and geranyl-substituted
coumarin derivatives with hitherto unprecedented skeletons - including dimeric coumarin derivatives
formed by Diels-Alder cycloadditions. Full structure elucidation by 2D NMR spectroscopy and assignment
of absolute configuration by electronic circular dichroism spectroscopy of these complex natural products
provide important reference data for future studies of related structures.
2. Results
Crude ethyl acetate extract of Gerbera piloselloides showed moderate inhibition of PTP1B and
α-glucosidase with IC50 values of 82.8± 0.96µg/mL and 35.9± 0.03µg/mL, respectively. Thus, two repeated
analytical-scale HPLC separations were microfractionated into two 96-well microplates each, which after
evaporation of the solvent and assaying using PTP1B andα-glucosidase, resulted in the dual high-resolution
PTP1B/α-glucosidase inhibition profile (biochromatogram) shown in Figure 1.
The biochromatogram shows that constituents in peaks 7 and 13–27 are correlated with both
PTP1B and α-glucosidase inhibitory activity. LC-HRMS analysis of the material eluted in the regions
marked fraction F1 (dark green) and F2 (orange) implied that most of the constituents eluting in these
regions have the same molecular formula C20H22O3. However, the material eluted with Fraction
1 did not show correlation with inhibitory activity in the biochromatogram. To compare active and
non-active compounds with the same molecular formula, Fraction 1 and 2 were selected for further
investigation together with the constituents eluted with peaks 1–27.
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Material eluted with peaks 1-27 and fractions 1 and 2 were collected manually by preparative-scale
HPLC. Fraction 2 was subsequently separated using an analytical-scale pentafluorophenyl (PFP) HPLC
column, and two successive separations were microfractionated. The dual high-resolution inhibition
profile of F2 is shown in Figure 2. This shows that the constituents eluting as peaks 13, 14 and 16–21
are correlated with α-glucosidase and/or PTP1B inhibitory activity. Thus, the extract seems to contain
multiple new compounds correlated with inhibitory activity towards both PTP1B and α-glucosidase -
one of many unique features of natural products.
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Structure Elucidation of Prenyl- and Geranyl Coumarin Derivatives
Based on information from the two biochromatograms shown in Figures 1 and 2,
material correlated with bioactivity as well as material suggested by LC-PDA-HRMS to be
prenyl- or geranyl coumarin derivatives were isolated by preparative-scale HPLC followed
Molecules 2020, 25, 1706 4 of 25
by analytical-scale HPLC as detailed in the Materials and Methods section. This led to
isolation of the new compounds 2, 5, 6, 8, 10, 11, 14, 15, 17–19, and 23–25 as well as
identification of the known compounds marmesin (1) [28], 7-demethylsuberosin (3) [29], apigravin
(4) [30], bothrioclinin (7) [31], (+)-2-[(2R)-6-acetyl-2,3-dihydro-5-hydroxybenzofuran-2-yl]- prop-2-enyl
15-methylbutanoate (8) [29], 3,5-bis-(isopent-2-en-1-yl)-4-hydroxyacetophenone (9) [32], 6-acetyl-
2,2-dimethyl-8-(3-methylbut-2-en-1-yl)-2H-chromene (12) [33], and mutisicoumarin B (16) [34] by
comparison of their 1H NMR data with data from the literature. Retention times, HRESIMS, and 1H
NMR data for 1, 3, 4, 7–9, and 12 are given in Table S1, Supplementary Material.
Compound 2 showed a [M + H]+ ion with m/z 277.1083 (C15H17O5+, ∆M −4.5 ppm), which
suggests the molecular formula C15H16O5. The 1H NMR spectrum shows characteristic signals for
a 1,2,3-trisubstituted benzene ring δ 7.12 (d, 7.4 Hz, H-6), δ 7.45 (dd, 8.3, 7.4 Hz, H-7) and δ 7.19 (d,
8.3 Hz, H-8)), two methyl singlets (δ 1.52, CH3-13 and δ 1.57, CH3-14) with HMBC correlations to C-4
(δ 163.7) and C-11 (δ 83.1), a methyl singlet (δ 2.72 CH3-12) with HMBC correlations to C-4a (δ 115.5),
C-5 (δ 139.0), and C-6 (δ 128.9), and two oxymethine signals at δ 4.58 (d, 4.1 Hz, H-9) and δ 3.75 (d,
4.1 Hz, H-10) with HMBC correlations to C-3 (δ 101.8) and C-2 (δ 164.7).
This suggested 2 to be the 9,10-dihydroxylated analogue of bothrioclinin (7) (Figure 3), and COSY,
ROESY, HSQC and HMBC correlations, of which selected correlations are shown in Figure 4, confirmed
this and allowed the full assignment of 1H and 13C NMR signals provided in Tables 1 and 2. The relative
configuration of 2 was established to be 9S*,10S* based on the coupling constant (3J = 4.1 Hz)
between H-9 and H-10, which suggests a cis configuration as also reported for cis-khellactone [35].
Finally, the absolute configuration of 2 was assigned 9S,10S by comparing the ECD spectrum of 2
(Figure S8, Supplementary Material) with ECD data of cis-khellactone [35]. Compound 2 is a new
compound for which the name gerbeloid 1 is proposed.
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Pos. 
δH (J, in Hz) 
2 6 10 5 
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11    11 1.46, s 
12 2.72, s 1.98, ddd (14, 13.0, 
3.3 Hz); 1.80, m 
2.25, m 
2.02, m 
12 1.47, s 
13 1.52, s 2.00, m; 1.68, m 1.77, m 1′ 2.95, dd (13.3, 5.5 Hz); 
2.68, dd (13.4, 7.8 Hz) 
14 1.57, s 3.52, d (10.0 Hz) 2.96, br s 2′ 4.31, dd (7.4, 5.7 Hz) 
16  4.73b; 4.81b 4.52, s; 4.54, s 4′ 4.76b; 4.83 b 
17  1.66, s 1.68, s 5′ 1.81, s 
18  2.72, s 2.76, s   
19  1.58, s 1.70, s   
a NMR data obtained with samples in methanol-d4. b Signals overlapping with residual solvent signal 
of methanol at δ 3.31, water at δ 4.87 or other signals from the molecule. 
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8 115.9 127.5 115.1 116.2 115.4 116.3 115.7 115.9 8 127.7 
8a 155.5 157.9 155.2 155.7 154.9 155.8 155.0 155.0 8a 156.8 
9 66.5 76.1 37.3 31.1 31.7 33.7 34.1 37.4 9 199.6 
10 73.8 95.9 126.0 121.7 121.0 123.1 122.8 38.4 10 26.1 
11 83.1 74.0 135.5 135.4 135.2 134.7 135.2 88.2 11 28.6 
12 23.3 36.1 31.4 30.5 30.3 32.2 32.0 40.6 12 28.6 
13 24.4 29.9 30.3 21.4 21.2 25.4 25.5 26.6 1′ 36.8 
14 22.9 78.3 45.4 41.0 40.3 47.1 46.2 48 2′ 75.8 
15  147.5 150 84.8 83.6 86.4 86.3 40.4 3′ 148.6 
16  111.0 110.6 22.4 23.3 22.6 23.9 23.4 4′ 111.1 
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Table 1. 1H NMR (600 MHz) Spectroscopic Data of 2, 5, 6, and 10 a.
Pos.
δH (J, in Hz)
Pos.
δH (J, in Hz)
2 6 10 5
6 7.12, d (7.4 Hz) 7.26, d (8.4 Hz) 6.99, d (7.5 Hz) 3 5.76, d (9.8 Hz)
7 7.45, dd (8.3,
7.4 Hz)
7.56, dd (8.4,
7.5 Hz)
7.29, dd (8.3,
7.5 Hz)
4 6.42, d (9.8 Hz)
8 7.19, d (8.3 Hz) 7.20, d (7.5 Hz) 7.03, d (8.3 Hz) 5 7.56, d (2.1 Hz)
9 4.58, d (4.1 Hz) .51, d (7.6 Hz) 3.83, d (10.5 Hz) 7 7.70, d (2.1 Hz)
10 3.75, d (4.1 Hz) 4.78, d (7.6 Hz) 5.32, br s 10 2.52, s
11 11 1.46, s
12 2.72, s 1.98, ddd (14, 13.0,
3.3 Hz); 1.80, m
2.25, m2.02, m 12 1.47, s
13 1.52, s 2.00, m; 1.68, m 1.77, m 1′ 2.95, dd (13.3, 5.5 Hz);
2.68, dd (13.4, 7.8 Hz)
14 1.57, s 3.52, d (10.0 Hz) 2.96, br s 2′ 4.31, dd (7.4, 5.7 Hz)
16 4.73b; 4.81b 4.52, s; 4.54, s 4′ 4.76b; 4.83 b
17 1.66, s 1.68, s 5′ 1.81, s
18 2.72, s 2.76, s
19 1.58, s 1.70, s
a NMR data obtained with samples in methanol-d4. b Signals overlapping with residual solvent signal of methanol
at δ 3.31, water at δ 4.87 or other signals from the molecule.
Table 2. 13C NMR (150 MHz) Spectroscopic Data of 2, 5, 6, 10, 11, 14, 15, 17, and 23 a.
Pos.
δC
Pos.
δC
2 6 10 11 14 15 17 23 5
2 164.7 161.4 165.5 162.6 164.1 162.7 163.9 165.2 2 78.9
3 101.8 102.7 106.4 100.5 102.9 99.7 102.9 103.9 3 132.0
4 163.7 171.1 171.4 182.2 162.4 181.8 163.5 163.6 4 122.8
4a 115.5 112.2 118.6 122.3 120 121 116.1 116.1 4a 121.7
5 139.0 138.5 138.8 133.0 138.0 141.3 138.2 138.1 5 126.4
6 128.9 115.5 127.6 133.1 128.2 128.9 128.7 128.9 6 130.7
7 132.8 133.8 30.7 1 8.9 131.6 133.0 132.0 132.1 7 133.1
8 115.9 127.5 115.1 116.2 115.4 116.3 115.7 115.9 8 127.7
8a 155.5 157.9 155.2 155.7 154.9 155.8 155.0 155.0 8a 156.8
9 66.5 76.1 37.3 31.1 31.7 33.7 34.1 37.4 9 199.6
10 73.8 95.9 126.0 121.7 121.0 123.1 122.8 38.4 10 26.1
11 83.1 74.0 135.5 135.4 135.2 134.7 135. 88.2 11 28.6
12 23.3 36.1 31.4 30.5 30.3 32.2 32.0 40.6 12 28.6
13 24.4 29.9 30.3 21.4 21.2 25.4 25.5 26.6 1′ 36.8
14 22.9 78.3 45.4 41.0 40.3 47.1 46.2 48 2′ 75.8
15 147.5 150 84.8 83.6 86.4 86.3 40.4 3′ 148.6
16 111.0 110.6 22.4 3.3 2 .6 23.9 23.4 4′ 111.1
17 19.5 19.2 23.4 23.4 23.3 23.4 27.6 5′ 17.7
18 21.1 23.2 25.5 25.6 27.1 27.3 34.1
19 30.8 23.4 25.4 25.0 20.1 20.3 17.9
a NMR data obtained with samples in methanol-d4.
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Compound 5 showed a [M + H]+ ion with m/z 287.1637 (C18H23O3+, ∆M 1.6 ppm), which suggests
the molecular formula C18H22O3. The 1H NMR spectrum of 5 displays characteristic signals for the
cis-coupled H-3 (δ 5.74, d, 9.8 Hz) and H-4 (δ 6.42, d, 9.8 Hz), the meta-coupled H-5 (δ 7.56, d, 2.1 Hz)
and H-7 (δ 7.70, d, 2.1 Hz), a methyl signal for CH3-10 (δ 2.52, s), and two methyl singlets for CH3-11
(δ 1.46, s) and CH3-12 (δ 1.47, s). This confirms that 5 possesses a 2,2-dimethyl-2H-chromene core
skeleton with an acetyl at C-6 and a second substituent at C-8, which based on the residual molecular
formulas, is in agreement with a hydroxyisoprenyl unit (C5H9O). The COSY spectrum revealed a
CH2-CH-O spin system, and HMBC correlations from H-1′ to C-8′ and C-8a′ as well as from H-2′, H-4′
and H-5′ to C-3′ confirmed a 2-hydroxy-3-methylbut-3-en-1-yl unit at C-8. Compound 5 gradually
degraded in solution, and it was therefore not possible to determine the absolute configuration at C-2′.
The structure of 5 is shown in Figure 3, selected COSY, ROESY and HMBC correlations are shown
in Figure 4, 1H NMR, COSY, ROESY, HSQC and HMBC spectra are provided in Figures S33–S38,
Supplementary Material, and fully assigned 1H and 13C NMR data are provided in Tables 1 and 2.
Compound 5 is a new compound for which the name gerbeloid 2 is proposed.
Compound 6 showed a [M + H]+ ion with m/z 343.1527 (C20H23O5+, ∆M 3.8 ppm) and a [M +
Na]+ ion with m/z 365.1359 (C20H22O5Na+, ∆M 0.1), which suggested the molecular formula C20H22O5
with a hydrogen deficiency index of 10. The 1H NMR spectrum of 6 shows characteristic signals of a
5-methylcoumarin moiety substituted at C-3 and C-4 (δ 7.26 (d, 8.4 Hz, H-6), δ 7.56 (dd, 8.4, 7.5 Hz,
H-7), δ 7.20 (d, 7.5 Hz, H-8), and δ 2.71 (s, CH3-18)) as also seen for 2 and 7, vide supra; leaving a residual
molecular formula of C10H16O3 and three hydrogen deficiency index numbers for the substituents at
C-3 and C-4. COSY correlations were observed between oxymethines H-9↔ H-10 and between H-12
↔ H-13↔ H-14, and with HMBC correlations from H-9 to C-14 and from H-14 to C-9 as well as from
H-10 and H-12 to the oxymethine C-11, this established the oxepane ring.
Furthermore, the prop-1-en-2-yl unit at C-14 was established by HMBC correlations from H-14 to
C-15, C-16 and C-17, and the methyl group at C-11 was established by HMBC correlations from H-19 to
C-11. Finally, the ether linkage between C-4 and C-10 to form the 2,3-dihydrofuran moiety was inferred
from the downfield shift of C-4 (δ 171.0) in 6 compared to 2 (δ 164.7) and 7 (δ 161.6), as also reported by
Qiang and co-workers for gerbelin 3 [13], as well as the need to establish a ring closure as determined
from the hydrogen deficiency index. Thus, the structure of 6 contains a rare furan-oxepane 5/7 ring
system formed by a geranyl unit.
The relative configuration 9R*,10S*,11R*,14R* was established based on the cis coupling constants
between H-9 and H-10 (3J = 7.6 Hz) as well as the ROESY correlations H-9↔ H-14, and between H-10
↔ CH3-19 (Figure 5A). An ECD spectrum of 6 indicated the material to be an enantiomeric mixture,
and subsequent chiral separation showed two enantiomers (6a and 6b) in a 1:1 ratio (Figure 5B).
The two enantiomers were isolated, and their experimental ECD spectra (Figure 5D) were as expected
completely opposite. After a conformational search, the 10 lowest-energy conformations of 6a were
obtained by energy minimization at the B3LYP/6-311G(d,p) level in CH3CN (Figure S4 and Tables
S2 and S3, Supplementary Material) and their ECD spectra calculated. The total Boltzmann-averaged
ECD spectrum is shown in Figure 5D, confirming 6a to be 9R,10S,11R,14R and 6b to be 9S,10R,11S,14S.
(Figure 5C), with an enantiomeric similarity index (∆ESI) of 0.80. Selected COSY, ROESY and HMBC
correlations are shown in Figure 5A, 1H NMR, COSY, ROESY, HSQC and HMBC spectra are provided
in Figures S39–S44, Supplementary Material, and fully assigned 1H and 13C NMR data are provided
in Tables 1 and 2. Compounds 6a and 6b are new compounds for which the names gerbeloid 3a and
gerbeloid 3b are proposed.
Compound 8 showed a [M + H]+ ion with m/z 319.1535 (C18H23O5+,∆M 1.6 ppm), which suggested
the molecular formula C18H22O5 with a hydrogen deficiency index of 8. The 1H NMR data of 8 are almost
identical with data reported for 2-[(2S*)-6-acetyl-2,3-dihydro-5-hydroxybenzofuran-2-yl]prop-2-enyl
3-methylbutanoate [29,36]. There is no optical rotation reported for this compound, but the optical
rotation [α]25 D + 60.8 (c 7.2 mM MeOH) of 8 has the opposite sign as the closely reported compounds
(−)-2S-6,12-dihydroxytremetone and (−)-(S)-2-(5-acetyl-6-hydroxy-2,3-dihydrobenzofuran-2-yl)allyl
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isobutyrate [37]. Furthermore, the experimental ECD spectrum of 8 shows positive Cotton effects
around 195 and 265 nm and a negative Cotton effect around 225 nm (Figure S8, Supplementary
Material), whereas the experimental and calculated ECD spectra of (−)-2S-6,12-dihydroxytremetone
show negative Cotton effects around 205 and 280 nm and a positive Cotton effect around 240 nm [37].
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Thus, 8 is tentatively assigned the R configura ion at C-2,
and 2-[(2S*)-6-acetyl-2,3 dihydro-5-h droxybenzofuran-2-yl]prop-2-enyl 3-methylbutanoat , pr viously
isolated from the closely related Leibnitzia an ndria Sch. Bip. [36] and Gerbera s xatilis [29], should most
likely also be assigned the R co figuration at C-2 based on biosynthetic arguments. Full assignment of the
HRMS nd 1H NMR data are included in Table S1, Suppleme tary Material, and 1H NMR, COSY, ROESY,
HSQC and HMBC spectra are provided in Figures S48–S52, Supplementary Material.
HRESIMS data for the material eluted with peaks 10–11, 14–15 and 17 showed [M + H]+ ions
suggesting that these compounds all have the formula C20H22O3. The 1D and 2D NMR spectra of 14 and
17 (Figures S72–S77 and Figures S88–S93, Supplementary Material) suggest structures consisting of the
same 5-methylcoumarin moiety substituted at C-3 and C-4 as seen in 2, 6 and 7. Furthermore, detailed
analysis of the NMR spectra suggested 14 and 17 to contain the same pyrano[3,2-c]coumarin core
skeleton that was obtained as product of the microwave-accelerated domino Knoevenagel hetero
Diels-Alder reaction between 4-hydroxycoumarin and citronellal [38], but with a methyl group at
C-5 and a double bond between C-10 and C-11 (Figure 3).
HMBC and COSY correlations support the structures of 14 and 17, with HMBC correlations
from H-18 to C-4, from H-9 to the carbonylic C-2 and the olefinic C-3, and from H-14 to the
oxygenated C-15 confirming the pyrano[3,2-c]coumarin skeleton (Figure 6). Compounds 14 and 17
are diastereomers, and the vicinal coupling 3JH9,H14 = 6.8 Hz for 14 and a ROESY correlation between
H-9 and H-14, support thes tw protons to be cis i 14; whereas th vicinal coupling 3J 9,H14 = 10.9 Hz
for 17 as ell as ROESY co relations between H-9 and CH3-18 and between H-14 and CH3- 9 support
these two protons to be tra s in 17. Both 14 and 17 are racemic mixtures, as en from the 1:1 peak
ratio upon chiral separation (Figures S1 and S2, Supplementary Material), and separation of the two
enantiomers allowed comparison of their experimental and calculated ECD spectra. The absolute
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configurations are therefore assigned 9R,14S for 14a and 9S,14R for 14b (with ∆ESI of 0.94), and 9R,14R
for 17a and 9S,14S for 17b (with ∆ESI of 0.86), as depicted in Figure 6. 1H NMR, COSY, ROESY, HSQC
and HMBC spectra are provided in Figures S72–S77 and Figures S88–S93, Supplementary Material,
and fully assigned 1H and 13C NMR data are provided in Tables 2 and 3. Compounds 14a/b and 17a/b
are new compounds for which the names gerbeloid 6a/gerbeloid 6b and gerbeloid 8a/gerbeloid 8b,
respectively, are proposed.
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Table 3. 1H NMR (600 MHz) Spectroscopic Data of 11, 14, 15, 17, and 23 a.
Pos. 11 14 15 17 23
6 7.13, d (7.3 Hz) 7.08, d (7.4 Hz) 7.14, d (7.5 Hz) 7.08, d (7.5 Hz) 7.11, d (7.5 Hz)
7 7.47, dd (8.3,
7.3 Hz)
7.39, dd (8.2,
7.4 Hz)
7.48, dd (8.3,
7.5 Hz)
7.39, dd (8.3,
7.5 Hz)
7.41, dd (8.4, 7.5 Hz)
8 7.22, d (8.3 Hz) 7.13, d (8.2 Hz) 7.23, d (8.3 Hz) 7.13, d (8.3 Hz) 7.16, d (8.3 Hz)
9 3.51, dd (6.7,
4.0 Hz)
3.42, dd (6.8,
5.4 Hz)
3.21, d (10.8 Hz) 3.11, d (10.9 Hz) 3.01, d (9.4 Hz)
10 6.25, br s 6.18, br s 6.24, m 6.24, m 2.72 (m)
12 2.02, m; 1.98, m 2.06, m; 1.98, m 2.19, br s 2.19, m 1.91, dd (13.0, 7.5 Hz); 2.07,
dd (12.8, 7.5 Hz)
13 2.04, m; 1.38, m 2.02, m; 1.34, m 1.96, m; 1.49, m 1.98, m; 1.47, m 1.76, dd (14.0, 7.5 Hz); 1.73, m
14 1.88, ddd (11.5, 6.1,
3.0 Hz)
1.88, ddd (11.8, 6.3,
3.0 Hz)
1.7, ddd (13.0,
10.8, 2.1 Hz)
1.71, ddd (12.7,
11.0, 2.0 Hz)
2.50, dd (8.1, 7.0 Hz)
16 2.80, s 2.69, s 2.81, s 2.70, s 2.74, s
17 1.67, s 1.68, s 1.68, s 1.68, s 1.56, s
18 1.51, s 1.57, s 1.54, s 1.61, s 1.40, s
19 1.42, s 1.41, s 1.26, s 1.26, s 0.88, s
a NMR data obtained with samples in methanol-d4.
Synthesis of the pyrano[3,2-c]coumarin core skeleton via the microwave-accelerated domino
Knoevenagel hetero Diels-Alder reaction between 4-hydroxycoumarin and citronellal [38], also provided
products with the pyrano[2,3-b]chromen-4-one core skeleton. This is because the final cyclisation of the
chromane-2,4-dione intermediate can occur via two different 4 + 2 cycloadditions, and one can predict
that the potential geran-1-ylidene-chromane-2,4-dione intermediate for biosynthesis of 14 and 17 (lactones)
could also lead to formation of the isomeric keto products with the pyrano[2,3-b]chromen-4-one core
skeleton (Scheme S1, Supplementary Material). The 13C NMR carbonyl resonances for C-4 in both 11 and
15 in fact suggest that the two compounds are chromone (keto) products, where C-4 is at δ 182.2 in 11
and δ 181.8 in 15 (Table 2). Additionally, HMBC correlations from CH3-18 and H-9 to C-2, from H-9 and
H-10 to C-3 and from H-8 and CH3-16 to C-4 in both compounds support the pyrano[2,3-b]chromen-4-one
core skeleton (Figure 6). Key COSY and HMBC correlations used for structure elucidation of 11 and 15
are shown in Figure 6. The relative configurations of 11 (9R*,14S*) and 15 (9R*,14R*) were established
based on the vicinal coupling between H-9 and H-14 (3JH9,H14 = 6.7 Hz cis in 11 and 3JH9,H14 = 10.8 Hz
trans in 15) (Tables 2 and 3) and ROESY correlations (Figure 6), showing that 11 and 15 are diastereomers.
By chiral resolution, two enantiomeric pairs 11a/b of 11 and 15a/b of 15 were obtained in a 1:1 ratio (Figure
S1, Supplementary Material), and ECD spectra were measured of each of the separated enantiomers.
Comparison of the experimental and calculated ECD spectra (Figure 6) allowed assignment of the absolute
configurations to be 9R,14S for 11a and 9S,14R for 11b (with ∆ESI of 0.98), and 9R,14R for 15a and 9S,14S
for 15b (with ∆ESI of 0.95). 1H NMR, COSY, ROESY, HSQC and HMBC spectra of 11 and 15 are provided
in Figures S61–S66 and Figures S78–S83, Supplementary Material, and 1H and 13C NMR data are provided
in Tables 2 and 3. Compounds 11a/b and 15a/b are new compounds for which the names gerbeloid
5a/gerbeloid 5b and gerbeloid 7a/gerbeloid 7b, respectively, are proposed.
Analysis of the 1D and 2D NMR data of 10 shows the 5-methylcoumarin skeleton (δ
6.99, H-6, δ 7.29, H-7, δ 7.03, H-8 and δ 2.76, CH3-18) as seen in 14 and 17, but with an
additional double bond (δ 150.0, C-15 and δ 110.6, C-16) and olefinic methylene group (δ 4.52 and
4.46, H-16) appearing and one methyl group disappearing (Tables 1 and 2). Thus, 10 was
identified as 4-hydroxy-5-methyl-3-(3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl)-2H-chromen-2-one,
the 10,11-dehydroanalog of an intramolecular domino Knoevenagel ene adduct previously reported [37].
Key COSY and HMBC correlations used for structure elucidation are shown in Figure 4, and 10 is
tentatively assigned the 9S*, 14R* configuration based on the coupling constants between H-9 and
H-14 (3JH9,H14 = 10.5 Hz trans) as also reported for the synthetic analog [38]. However, keto-enol
tautomerism did neither allow chiral separation or acquisition of ECD spectra, and 10 was gradually
degraded in solution. 1H NMR, COSY, ROESY, HSQC and HMBC spectra are provided in Figures
S56–S60, Supplementary Material, and fully assigned 1H and 13C NMR data are provided in Tables 1
and 2. Compound 10 is a new compound for which the name gerbeloid 4 is proposed.
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HRESIMS data for the material eluted with peaks 18-19 and 24-25 provided [M + H]+ ions, showing
that these compounds all have the formula C30H28O6 (see details in the Materials and Methods section),
suggesting them to be dimers of prenyl-substituted coumarin derivatives. Furthermore, chemical shift
values of C-4 (δ 181.7 and 181.9) (Table 4) in 19 and 25, respectively, showed each of these to consist of
a coumarin (lactone) unit and a chromen-4-one (keto) unit, whereas 18 and 25 consist of two coumarin
units each. Detailed analyses of 1D and 2D NMR data for 18 and 25 show that they consist of two
pyrano[3,2-c]coumarin units joined together by bonds between C-9 and C-13′ and between C-10 and
C-9′, and comparison with NMR data reported for dibothrioclinin I and II [11], show that 18 and 25 are
diastereomers of these. This was further supported by COSY and HMBC correlations (key correlations
seen in Figure 7).
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Table 4. 13C NMR (150 MHz) Spectroscopic Data of 18, 19, 24, and 25 a.
Pos.
δC
Pos.
δC
18 19 24 25 18 19 24 25
2 163.5 163.3 163.9 163.0 2′ 165.0 163.8 163.5 163.4
3 103.0 99.6 99.2 102.6 3′ 101.3 104.9 109.0 109.0
4 167.5 181.7 181.9 164.2 4′ 164.0 166.3 163.1 163.0
4a 115.1 121.5 122.2 115.8 4a′ 115.7 115.4 116.0 115.6
5 138.3 141.2 141.3 138.3 5′ 138.0 138.3 138.3 138.3
6 128.7 128.7 128.6 128-7 6′ 128.5 128.5 128.4 128.8
7 132.4 133.0 131.9 132.1 7′ 131.9 132.0 132.7 132.2
8 115.6 116.4 115.4 115.6 8′ 115.3 115.9 115.9 115.8
8a 154.9 155.8 155.7 155.1 8a′ 154.7 155.1 155.1 155.2
9 28.8 26.2 25.9 26.4 9′ 28.9 28.8 26.5 26.7
10 52.9 45.0 54.1 53.1 10′ 38.2 31.9 30.2 30.5
11 81.4 86.3 86.4 85.0 11′ 83.3 80.8 81.0 81.5
12 23.5 22.4 22.3 23.9 12′ 23.6 23.6 23.4 23.7
13 26.8 24.9 28.3 28.9 13′ 43.2 40.3 40.1 40.8
14 19.7 28.9 20.5 21.2 14′ 27.8 28.3 28.9 29.3
a NMR data obtained with samples in methanol-d4.
The core cyclohexane of 18 was identified as a chair conformation with axial-axial couplings
between H-9 and H-10 and between H-9 and H-13′ax (JH9,H10 = JH9,H-13′ax = 12 Hz) and 1,3-diaxial
ROEs between H-10, H-10′ax, and H-13′ax. With equatorial position of H-9′ and CH3-14′, as seen
from coupling constants and ROEs to H-10, H-10′ax, and H-13′ax, the relative configuration of 18 was
established as 9R*,10S*,9′R*,11′S*. Contrary to this, the core cyclohexane of 25 was identified as a
boat conformation, with very strong ROE correlation between H-9 and H-10′endo (and ROEs to H-9′,
H-9′, H-13′eq and CH3-14′ on the same side of the plane) and 1,3-diaxial ROEs between H-10 and
H-13′ax. The relative configuration of 25 was therefore established as 9R*,10S*,9′S*,11′R* (Figure 7).
Two pairs of enantiomers (18a and 18b, 25a and 25b) with the peak area ratios 1:1 were separated
by chiral HPLC chromatography (Figures S2 and S3, Supplementary Material). Comparison of the
experimental and calculated ECD spectra (Figure 7) allowed assignment of the absolute configurations
to be 9R,10S,9′R,11′S for 18a and 9S,10R,9′S,11′R for 18b (with ∆ESI of 0.93), and 9R,10S,9′R,11′S for
25a and 9S,10R,9′S,11′R for 25b (with ∆ESI of 0.82). 1H NMR, COSY, ROESY, HSQC and HMBC spectra
are provided in Figures S94–S99 and S118–S123, Supplementary Material, and fully assigned 1H and
13C NMR data are provided in Tables 4 and 5. Compounds 18a/b and 25a/b are new compounds for
which the names gerbeloid 9a/gerbeloid 9b and gerbeloid 13a/gerbeloid 13b, respectively, are proposed.
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Table 5. 1H NMR (600 MHz) Spectroscopic Data of 18, 19, 24, and 25 a.
Pos.
δH (J, in Hz)
18 19 24 25
6 7.16, d (7.4 Hz) 7.13, d (7.3 Hz) 7.13, d (7.5 Hz) 7.07, d (7.5 Hz)
7 7.46, dd (8.2, 7.4 Hz) 7.48, dd (8.2, 7.3 Hz) 7.40, dd (8.2, 7.5 Hz) 7.38, dd (8.0, 7.5 Hz)
8 7.19, d (8.2 Hz) 7.24, d (8.0 Hz) 7.15, d (8.2 Hz) 7.11, d (8.0 Hz)
9 2.68, td (12.0, 4.2 Hz) 3.10, br dt (13.1, 6.3 Hz) 2.72, td (12.7, 4.2 Hz) 2.68, td (12.6, 4.2 Hz)
10 2.17, dd (12.0, 1.9 Hz) 2.15, br d (6.6 Hz) 1.62, dd (12.4, 3.2 Hz) 1.62, dd (12.4, 3.1 Hz)
12 2.70, s 2.76, s 2.78, s 2.69, s
13 1.91, s 1.67, s 1.79, s 1.87, s
14 1.10, s 1.77, s 1.43, s 1.44, s
6′ 7.09, d (7.4 Hz) 7.15, d (7.5 Hz) 7.09, d (7.6 Hz) 7.10, d (7.8 Hz)
7′ 7.39, dd (8.4, 7.4 Hz) 7.44, dd (8.3, 7.5 Hz) 7.46, dd (8.4, 7.6 Hz) 7.41, dd (8.3, 7.8 Hz)
8′ 7.12, d (8.4 Hz) 7.17, d (8.3 Hz) 7.21, d (8.4 Hz) 7.15, d (8.3 Hz)
9′ 3.59, q (2.7 Hz) 3.50, br q 3.08, q (3.2 Hz) 3.13, q (3.1 Hz)
10′ 2.22, dd (13.2, 2.8 Hz)1.90, dt (13.2, 2.8 Hz)
2.31, dd (14.1, 2.8 Hz);
1.82, dt (14.1, 2.5 Hz)
2.29, dd (14.0, 3.4 Hz);
1.53, dd (14.0, 2.6 Hz)
2.28, dd (13.9, 3.4 Hz);
1.55, dd (13.9, 2.7 Hz)
12′ 2.81, s 2.84, s 2.73, s 2.74, s
13′ 3.51, ddd (14.0, 4.2,
2.6 Hz); 1.47,
dd (14.0, 12.0 Hz)
3.02, ddd (14.2, 5.5,
2.5 Hz); 1.71, dd (14.2,
13.1 Hz)
3.80, dd (14.7,
4.2 Hz); 1.40 dd (14.7,
13.1 Hz)
3.68, dd (14.8, 4.3 Hz);
1.48, dd (14.8, 13.0 Hz)
14′ 1.61, s 1.61, s 1.78, s 1.76, s
a NMR data obtained with samples in methanol-d4.
The 1H NMR data of 19 and 24 show similar patterns for H-6, H-7, H-8 and H-6′, H-7′, H-8′ in the
aromatic region as seen for 18 and 25, showing the methyl groups at C-5 and C-5′. However, as stated
above, 19 and 24 each consist of a coumarin (seen from the chemical shift values of δ 163.8 and δ
163.5 for C-2′ and δ 166.3 and δ 163.1 for C-4′ in 19 and 24, respectively) and a chromen-4-one unit
(seen from the chemical shift values of δ 163.3 and δ 163.9 for C-2 and δ 181.7 and δ 181.9 for C-4 in
19 and 24, respectively). HMBC correlations from CH3-18 and H-9 to C-2, from H-9 and H-10 to
C-3, and from H-8 and CH3-12 to C-4 support the pyrano[2,3-b]chromen-4-one skeleton, whereas
HMBC correlations from H-9′ to C-2′, H-9′ and H-10 to C-3′, and from CH3-14′ to C-4′ support the
pyrano[3,2-c]coumarin skeleton (Figure 7). Furthermore, HMBC correlations from H-9 to C-11′ and
C-13′ as well as from H-10 to C-3′ and C-9′ and from H-9′ to C-10 and C-11 proved the bridging between
the pyrano[2,3-b]chromen-4-one and the pyrano[3,2-c]coumarin skeleton as shown in Figures 3 and 7.
Based on analysis of coupling constants and ROESY correlations (Figure 7), 19 was assigned the relative
configuration 9R*,10R*,9′R*,11′R* and 24 was assigned the relative configuration 9R*,10S*,9′S*,11′S*.
Additionally, X-ray crystal structure analysis of the racemate of 19 yielded the structure shown in
perspective drawing (ORTEP-3) [39] in Figure 8. This agrees with the structure established based on
the NMR data, confirming the 9R*,10R*,9′R*,11′R* configuration of 19.
After chiral separation of 19 and 24 (1:1 ratios of enantiomers 19a, 19b and 24a, 24b, see Figures
S2 and S3, Supplementary Material), ECD spectra of both pairs of enantiomers were acquired. These are
shown in Figure 7, and comparison with the calculated ECD spectra of 19a and 24a allowed assignment
of the absolute configurations to be 9R,10R,9′R,11′R for 19a and 9S,10S,9′S,11′S for 19b (with ∆ESI
of 0.77), and 9R,10S,9′S,11′S for 24a and 9S,10R,9′R,1′R for 24b (with ∆ESI of 0.87) (Figure 7). 1H
NMR, COSY, ROESY, HSQC and HMBC spectra are provided in Figures S100–S105 and S112–S117,
Supplementary Material, and fully assigned 1H and 13C NMR data are provided in Tables 4 and 5.
Compounds 19a/b and 24a/b are new compounds for which the names gerbeloid 10a/gerbeloid 10b
and gerbeloid 12a/gerbeloid 12b, respectively, are proposed.
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Compound 23 showed a [M + H]+ ion with m/z 311.1641 (C20H23O3+, ∆M 0.2 ppm) and a [M +
Na]+ ion with /z 333.1446 ( 2O3Na+, ∆M 4.5 ppm), which suggested the molecular formula
C20H22O3, with a hydrogen deficiency index of 10. The 1H and 13C NMR spectra of 23 show signals
corresponding to H-6, H-7 and H-8 in the aromatic region and the methyl group at C-5 as well as
characteristic chemical shifts for C-2 (δ 165.2), C-3 (δ 103.9), and C-4 (δ 163.6) as also observed for
14 and 17, suggesting they share the same 5-methylcoumarin skeleton. The pyrano[3,2-c]coumarin
core skeleton is supported by HMBC correlations from CH3-16 and CH3-17 to C-4, from CH3-17 to
C-10, and from H-9 to C-2 and C-4 (Figure 9) as well as correlations in the COSY spectrum between
H-9 and H-10. In fact, the COSY spectrum showed correlations corresponding to the H-9↔H-10↔
H-14↔H-13↔H-12 spin system, and HMBC correlations from H-12 to C-11 and C-17 revealed the
cyclopentane ring system, whereas HMBC correlations from H-9, H-14, CH3-18 and CH3-19 to -15 and
from H-18 and H-19 to C-9 and C-14 revealed the dimethylated cyclobutane ring system. Thus, 23 was
identified as a 5-methylcoumarin with a 6/5/4 ring system fused at C-3 and C-4. Two coumarins with
similar 6/5/4 ring systems have been reported before [40], but linked to either C-5 and C-6 or C-7 and
C-8 of the coumarin moiety; and the NMR data for the 6/5/4 ring system of the previously reported
compounds resemble those observed for 23 (Tables 2 and 3) [40,41]. The coupling constants between
H-9 and H-10 (3J = 9.4 Hz) and between H-10 and H-14 (3J = 8.1 Hz) are in close agreement with those
previously reported for a similar 6/5/4 ring system with H-9, H-10 and H-14 being cis, and thus o
the same side of the molecule. Similarly, the ROESY correlations between H-9↔ H-18↔ H-14↔
H-13A and H-10↔H-17↔H-12A show these to be on one plane of the molecule, whereas ROESY
correlations between H-19 and H12B/H-13B shows these to be on the other plane of the molecule - and
thus the relative configuration of 23 is 9R*,10R*,11R*,14S*.
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Chiral resolution of 23 gave two enantiomers (23a and 23b) in a 1:1 ratio (Figure S2, Supplementary
Material), and comparison of the ECD spectra of 23a and 23b with the ECD spectrum calculated for
23b (Figure 9), allowed assignment of the absolute configuration to be 9R,10R,11R,14S for 23a and
9S,10S,11S,14R for 23b, respectively, with ∆ESI of 0.88. 1H NMR, COSY, ROESY, HSQC and HMBC
spectra are provided in Figures S106–S111, Supplementary Material, and fully assigned 1H and 13C
NMR data are provided in Tables 2 and 3. Compounds 23a/b are new compounds for which the names
gerbeloid 11a/gerbeloid 11b are proposed.
The material eluted with peaks 14–19 and 23–25 were correlated with both α-glucosidase and
PTP1B inhibitory activity in the high-resolution inhibition profile (Figures 1 and 2). Due to limited
amount of material isolated of the racemic mixtures as well as the individual enantiomers after
chiral separation, it was not possible to make dilution series to obtain full dose-response curves.
However, for the racemic mixtures of 17–19, 24 and 25, it was possible to test the inhibitory activity at a
single concentration between 32.2 and 201.6 µM. The results are provided in Table 6 and show that the
tested compounds show weak to moderate inhibitory activity towards both α-glucosidase and PTP1B.
Table 6. Percentage inhibition of 17–19, 24 and 5 against α- lucosidase and PTP1B at the concentration
shown i brackets.
Compound α-Glucosidase (µM) PTP1B (µM)
17 32% (201.6) N.D.a
18 40% (159.1) N.D.a
19 48% (129.1) 67% (64.4)
24 51% (129.1) 47% (32.2)
25 45% (64.4) 32% (129.1)
a N.D. Not detected.
The reported values may be underestimated, beca e typically only one enantiomer of a racemic
mixture is an ctive inhibitor of the target enzym . Thus, isolation of more material a d subsequent
chiral separation ar needed to obtain full dose-response curves for both enantiomers in both the
α-glucosidase and th PTP1B assay, as well as for being able t st the mode of inhibition of the
many compounds correlated ith one or both activities. The only prior study with dual i hibitory
activity of PTP1B and α-glucosidase with this kind of compounds, is a recent study with a series of
prenylated coumarins from Angelica decursiva, showing weak α-glucosidase inhibitory activity with
IC50 values ranging from 65 to 172 µM, and PTP1B inhibitory activity with IC50 values ranging from
5 to 59 µM.
The coumarin skeleton is synthesized from acetyl-CoA and malonyl-CoA through the polyketide
pathway in plants [42]. Inspired by the biosynthetic pathway of tetrahydrocannabinolic acid (THCA)
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in Cannabis sativa [43], the monoterpenoid-coumarins identified in this study are plausibly first added
a monoterpenoid chain to C-3 of the coumarin skeleton, catalyzed by prenyl transferase (Pathway
1 in Figure 10). As mentioned above, [4 + 2] cycloaddition reactions have been utilized for the
total synthesis of structures similar to 11, 14, 15 and 17 (Scheme S1, Supplementary Material) [38],
and therefore cyclisations via different Diels-Alder cycloadditions between the monoterpenoid and
coumarin, followed by oxidations or reductions catalyzed by oxidoreductase enzymes, could be
involved in the formation of 2, 6, 7, 10, 11, 14–17 and 23 (Figure 10).
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There re o prior studies on the biosynthesis of coumarins related to the dimeric coumarin
derivatives isolated in this study, but total synthesis of pyranylquinoline alkaloids [44] suggests
mechanisms for the plausible biosynthetic route for 18, 19, 24 and 25 presented as pathway 2 in
Figure 10. In this route, the precursor of 18, 19, 24 and 25 is suggested to be 7, which is seen as a
major peak in the ethyl acetate extract of G. piloselloides (Figure 1). The key steps in the dimerization
of 7 include a ring opening, a hydride shift and a 1,4-addition (Figure 10), followed by 1,4-addition
reactions leading to 18 and 25 with two coumarin moieties or 19 and 24 with one coumarin moiety and
one chromone moiety in the structure (Figure 10).
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3. Materials and Methods
3.1. Plant Material and Extraction Procedure
Aerial parts of Gerbera piloselloides (L.) Cass was collected from Sandaohe Village, Duyun City,
Guizhou Province, People′s Republic of China in September 2017 and authenticated by Associate Prof.
Chunhua Liu (Provincial Key Laboratory of Pharmaceutics in Guizhou Province, Guizhou Medical
University). A voucher specimen (accession number JX20170208) is deposited at the Guizhou Medical
University. The air-dried material (1.7 kg) was milled and extracted three times with 2 L ethyl acetate
(1 h of ultra-sonication for each extraction). The combined extracts were filtered and concentrated
under reduced pressure to give 20 g of dark green crude extract.
3.2. Chemicals and Reagents
Recombinant human protein tyrosine phosphatase 1B (PTP1B) (BML-SE332-0050, EC
3.1.3.48) was purchased from Enzo Life Sciences (Farmingdale, NY, USA). α-Glucosidase from
Saccharomyces cerevisiae type I, lyophilized powder (EC 3.2.1.20), p-nitrophenyl α-D-glucopyranoside
(p-NPG), p-nitrophenyl phosphate (pNPP), acarbose, sodium phosphate monobasic dihydrate,
disodium phosphate dibasic, sodium azide, sodium chloride, dimethyl sulfoxide (DMSO),
tris-(hydroxymethyl)-aminomethane (Tris), bis-(2-hydroxyethyl)-imino-tris-(hydroxymethylmethane)
(Bis-Tris), N,N,N′,N′-ethylenediaminetetraacetate (EDTA), dithiothreitol (DTT), methanol-d4, and HPLC
grade acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO, USA), and formic acid (FA)
was purchased from Merck (Darmstadt, Germany). Water was purified by deionization and filtration
through a 0.22 µm membrane (Millipore, Billerica, MA, USA).
3.3. LC-PDA-HRMS
LC-PDA-HRMS analyses were performed on a model 1260 analytical-scale HPLC system consisting
of a G1322A degasser, a G1311A quaternary pump, a G1316A thermostatted column compartment,
and a G1315A photodiode-array detector (Agilent, Santa Clara, CA, USA) and a Bruker micrOTOF-Q
II high-resolution mass spectrometer (Bruker Daltonik, Bremen, Germany). The column eluate was
connected to a T-piece splitter directing 1% of the flow to the mass spectrometer and 99% of the flow
the photodiode-array detector. The micrOTOF-Q II mass spectrometer, equipped with an ESI source,
was operated in the positive-ion mode using a drying temperature of 200 ◦C, a capillary voltage of
4100 V, a nebulizer pressure of 2.0 bar, and a drying gas flow of 7 L/min. A solution of sodium formate
clusters was injected automatically at the beginning of each run to enable internal mass calibration.
Chromatographic separations were performed at 40 ◦C on a Luna C18(2) column, 150 × 4.6 mm i.d.,
3 µm particle size, 100 Å pore size (Phenomenex, Torrance, CA, USA) at a flow rate of 0.5 mL/min
and using a binary gradient of mobile phase A (CH3CN:H2O 5:95 + 0.1% FA) and mobile phase B
(CH3CN:H2O 95:5 + 0.1% FA). Chromatographic separation and mass spectrometry were controlled
using Hystar ver. 3.2 software (Bruker Daltonik).
3.4. Dual High-Resolution PTP1B/α-Glucosidase Inhibition Profiling
High-performance liquid chromatography (HPLC) was performed with an Agilent 1200 series
instrument consisting of a G1322A degasser, a G1311A quaternary solvent pump, a G1313A
high-performance auto sampler, a G1316A thermostatic column compartment, a G1315B
photodiode-array detector, and a G1364C fraction collector, all controlled by Agilent ChemStation
software ver. B.03.02. 10 µL of crude extract (50 mg/mL in methanol) was separated at 40 ◦C on a
Phenomenex Luna C18(2) column (150 mm × 4.6 mm i.d., 3 µm particle size, 100 Å pore size), using the
following binary elution gradient of mobile phase A (CH3CN:H2O 5:95 + 0.1% FA) and mobile phase
B (CH3CN:H2O 95:5 + 0.1% FA) at a flow rate of 0.5 mL/min: 0 min, 10% B; 30 min, 80% B; 50 min,
100% B and 65 min, 100% B. The eluate from 2 to 65 min was fractionated into 176 wells of two 96-well
plates (excluding 8 wells in each plate for the blank control), to give a resolution of 2.8 data points
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per min. 10 µL of fraction F2 was separated at 40 ◦C on a Kinetex pentafluorophenyl (PFP) column
(150 mm × 4.6 mm i.d., 2.6 µm particle size, 100 Å pore size) (Phenomenex) using the following binary
elution gradient of mobile phase C (MeOH:H2O 5:95 + 0.1% FA) and mobile phase D (MeOH:H2O
95:5 + 0.1% FA) at a flow rate of 0.5 mL/min: 0 min, 60% D; 15 min, 80% D; 30 min, 100% D and
45 min, 100% D. The eluate from 2 to 40 min was fractionated into one 96-well plate (88 wells) to give
a resolution of 2.3 data points per min. The fractions in all wells were subsequently evaporated to
dryness under reduced pressure, and after PTP1B and a-glucosidase assaying, dual high-resolution
PTP1B/α-glucosidase inhibition profiles of crude extract and fraction F2 were constructed as detailed
by Wubshet and coworkers [45].
3.5. Targeted Isolation of PTP1B/α-Glucosidase Inhibitors and Major Metabolites
Crude ethyl acetate extract (100 mg/mL in MeOH) was separated using a preparative-scale Agilent
1100 HPLC system comprising two G1361A preparative-scale solvent delivery pumps, a G2260A
autosampler, and a G1365B multiple wavelength detector, controlled by Agilent ChemStation software
ver. B.01.01. Injections (900 µL) were separated at room temperature on a Phenomenex Luna C18
column (250 mm × 21.2 mm i.d., 5 µm particle size) using the following binary gradient of mobile
phase A and B, vide supra, at a flow rate of 17 mL/min: 0 min, 10% B; 30 min, 80% B; 50 min, 100% B,
65 min, 100% B. Manual collection of eluate from 15.8 to 16.5 min (peak 1), 17.8 to 18.6 min (peak 2),
25.0 to 25.6 min (peak 3), 25.8 to 26.2 min (peak 4), 26.3 to 26.7 min (peak 5), 26.8 to 28.1 min (peak 6),
30.1 to 31.3 min (peak 7), 32.0 to 32.5 min (peak 8), 32.5 to 33.1 min (peak 9), 35.7 to 39.6 min (Fraction
1), 39.8 to 41.5 min (Fraction 2), 41.6 to 42.3 min (peak 23), 42.7 to 43.4 min (peak 24), 44.2 to 44.9 min
(peak 25) and 53.1 to 54.4 min (peaks 26-27) afforded 11 mg of peak 1, 10 mg of peak 2, 14.2 mg of peak
3, 9.4 mg of peak 5, 10.8 mg of peak 6, 85.6 mg of peak 7, 9.8 mg of peak 8, 51.1 mg of peak 9, 54.2 mg
of Fraction 1, 67.0 mg of Fraction 2, 13.1 mg of peak 23, 7.8 mg of peak 24, 12.8 mg of peak 25 and
4.4 mg of peaks 26–27. Compounds 5 and 6 were purified from the material eluted as peaks 5 and 6 on
the above-mentioned analytical-scale HPLC system and PFP column (10 µL injections of a 25 mg/mL
solution, flow rate 0.5 mL/min) using the following binary gradient elution profile of mobile phase C
and D: 0 min, 60% D; 15 min, 80% D; 35 min, 90% D; 45 min, 100% D and 47 min, 60% D. This yielded
1.2 mg of 5 (tR = 10.6 min) and 1.0 mg of 6 (tR = 14.3 min). Compounds 10-12 were purified from
fraction F1 (10 µL injections of a 20 mg/mL solution, flow rate 0.5 mL/min) using the following binary
gradient elution profile of mobile phase C and D: 0 min, 70% D; 10 min, 80% D; 30 min, 81% D; 45 min,
90% D and 55 min, 100% D. This afford 0.7 mg of 10 (tR = 17.0 min), 1.2 mg of 11 (tR = 18.6 min) and
0.8 mg of 12 (tR = 19.5 min). Compounds 14–19 were purified from fraction F2 (10 mL injections of
a 20 mg/mL solution, flow rate 0.5 mL/min) using the following binary gradient elution profile of
mobile phase C and D: 0 min, 60% D; 15 min, 80% D; 30 min, 100% D, 45 min, 100% D. This yielded
1.6 mg of 14 (tR = 26.3 min), 1.5 mg of 15 (tR = 27.0 min), 2.5 mg of 16 (tR = 28.2 min), 2.1 mg of 17
(tR = 29.1 min), 1.2 mg of 18 (tR = 31.5 min), and 1.7 mg of 19 (tR = 31.8 min). Compounds 23, 24 and 25
were purified after repeated separation of the material eluted as peaks 23, 24 and 25 (15 mL injections
of a 25 mg/mL solution) using the following binary gradient of mobile phase C and D as indicated
after each compound: 23 (tR = 28.4 min): 0 min, 60% D; 15 min, 80% D; 30 min, 100% D; 45 min, 100%
D and 47 min, 60% D; 24 (tR = 26.0 min) and 25 (tR = 27.0 min): 0 min, 70% D; 10 min, 90% D; 35 min,
95% D; 45 min, 100% D and 55 min, 100% D. This gave 1.5 mg of 23, 1.1 mg of 24 and 1.7 mg of 25.
3.6. Chiral Separation of Enantiomers
Chiral resolution of 6, 15, 18, 19, 23, 24 and 25 was performed at room temperature on a Dionex
Ultimate instrument consisting of a LPG-3200BX pump and a MWD-3000SD UV detector, both
controlled by Chromeleon software ver. 6.80 (Thermo Fisher Scientific, Waltham, Ca, USA), and with a
Rheodyne 9725I injector with 10 µL loop. Enantiomers of compounds 6, 15, 18, 19, 23 and 24 were
separated at a flow rate of 1 mL/min on a Chiralpak AD-H column (250 × 4.6 mm i.d., 5.0 µm particle
size) (Chiral Technologies, West Chester, PA, USA) isocratically eluted with the following mixtures
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of isopropanol (mobile phase E) and heptane (mobile phase F): 20% E and 80% F for 6; 1% E and
99% F for 15; 10% E and 90% F for 18, 19 and 24; 5% E and 95% F for 23 and 24. Enantiomers of
compound 14 were separated at a flow rate of 0.8 mL/min on a Chiralpak OD-H column (250 × 4.6 mm
i.d., 5.0 µm particle size) (Chiral Technologies) isocratically eluted at room temperature with 2% E
and 98% F. Enantiomers of compounds 11 and 17 were separated at a flow rate of 1 mL/min on a Lux
Amylose-2 column (250 × 4.6 mm i.d., 5.0 µm particle size) (Chiral Technologies) isocratically eluted
with 1% E and 99% F. The chiral resolution of ten pairs of enantiomers gave 0.40 mg/0.40 mg of 6a/b,
0.15 mg/0.15 mg of 11a/b, 0.20 mg/0.20 mg of 14a/b, 0.20 mg/0.17 mg of 15a/b, 0.50 mg/0.40 mg of 17a/b,
0.17 mg/0.20 mg of 18a/b, 0.20 mg/0.20 mg of 19a/b, 0.19 mg/0.15 mg of 23a/b, 0.30 mg/0.20 mg of 24a/b
and 0.18 mg/0.20 mg of 25a/b.
Compound 2: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 203, 230, 282-293 nm; 1H and 13C NMR data, see Tables 1
and 3; ECD (c 9.0 mM, CH3CN) λmax (∆ε) 207 (−7.1), 223.5 (+1.02), 264 (+0.31), 294 (+0.91) nm;
(+)HRESIMS m/z [M + H]+ calcd for C15H17O5+, 277.1071, found 277.1083, ∆M −4.5 ppm.
Compound 5: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 199, 260, 294 nm; 1H and 13C NMR data, see Tables 1 and 3;
(+)HRESIMS m/z [M + H]+ calcd for C18H23O3+, 287.1642, found 287.1637, ∆M +1.6 ppm; [M + Na]+
calcd for C18H22O3Na+, 309.1461, found 309.1463, ∆M −0.6 ppm.
Compound 6: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 198, 212, 248, 348 nm; 1H and 13C NMR data, see Tables 1
and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O5+, 343.1540, found 343.1527, ∆M +3.8 ppm; [M +
Na]+ calcd for C20H22O5Na+, 365.1359, found 365.1355, ∆M +1.2 ppm.
Compound 6a: ECD (c 5.8 mM, CH3CN) λmax (∆ε) 201 (−19.0), 220 (+14.0), 250 (+7.1), 282 (−2.2),
312 (+4.4), 325 (+3.6) nm.
Compound 6b: ECD (c 5.8 mM, CH3CN) λmax (∆ε) 201 (+19.0), 220 (−14.0), 250 (−7.1), 282 (+2.2),
312 (−4.4), 325 (−3.6) nm.
Compound 8: white, amorphous powder; [α]D25 + 60.8 (c 7.2 mM MeOH); HPLC-UV (MeOH in
H2O + 0.1% FA) λmax 204, 235, 266, 365 nm; 1H NMR data, see Table S1, Supplementary Material; ECD
(c 6.3 mM, CH3CN) λmax (∆ε) 195 (+17.5), 223.5 (−8.2), 266.1 (+2.3) nm; (+)HRESIMS m/z [M + H]+
calcd for C18H23O5+, 319.1540, found 319.1535, ∆M +1.6 ppm.
Compound 10: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 207, 225-237, 294, 310 nm; 1H and 13C NMR data, see Tables 1
and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O3+, 311.1642, found 311.1644, ∆M −0.7 ppm; [M +
Na]+ calcd for C20H22O3Na+, 333.1461, found 333.1460, ∆M +0.3 ppm.
Compound 11: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 207, 229, 275, 299 nm; 1H and 13C NMR data, see Tables 1
and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O3+, 311.1642, found 311.1644, ∆M −0.7 ppm; [M +
Na]+ calcd for C20H22O3Na+, 333.1461, found 333.1460, ∆M +0.3 ppm.
Compound 11a: ECD (c 2.4 mM, CH3CN) λmax (∆ε) 193 (+4.0), 223 (−2.2), 300 (−0.2) nm.
Compound 11b: ECD (c 2.4 mM, CH3CN) λmax (∆ε) 193 (−6.5), 223 (+3.7), 300 (+0.8) nm.
Compound 12: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 200, 231, 260, 300–310 nm; 1H NMR data, see Table S1,
Supplementary Material; (+)HRESIMS m/z [M + H]+ calcd for C18H23O2+, 271.1693, found 271.1701,
∆M −3.1 ppm; [M + Na]+ calcd for C18H22O2Na+, 293.1512, found 293.1515, ∆M −1.0 ppm.
Compound 14: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 206, 227, 283-306, 319 nm; 1H and 13C NMR data, see Tables 1
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and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O3+, 311.1642, found 311.1644, ∆M −0.7 ppm; [M +
Na]+ calcd for C20H22O3Na+, 333.1461, found 333.1460, ∆M +0.3 ppm.
Compound 14a: ECD (c 3.2 mM, CH3CN) λmax (∆ε) 194 (−1.0), 210 (+2.0), 237 (+0.5), 280 (−0.4) nm.
Compound 14b: ECD (c 3.2 mM, CH3CN) λmax (∆ε) 194 (+1.2), 210 (−1.7), 233 (−0.5), 280 (+0.5) nm.
Compound 15: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 206, 231, 278–298 nm; 1H and 13C NMR data, see Tables 2
and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O3+, 311.1642, found 311.1644, ∆M −0.7 ppm; [M +
Na]+ calcd for C20H22O3Na+, 333.1461, found 333.1460, ∆M +0.3 ppm.
Compound 15a: ECD (c 3.2 mM, CH3CN) λmax (∆ε) 190 (+19.3), 215 (−10.5), 250 (−1.9), 273 (−3.9),
292 (−3.6) nm.
Compound 15b: ECD (c 2.7 mM, CH3CN) λmax (∆ε) 190 (−21.6), 215 (+13.5), 250 (+3.3), 273 (+5.0),
292 (+4.7) nm.
Compound 17: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 207, 221, 293–309 nm; 1H and 13C NMR data, see Tables 2
and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O3+, 311.1642, found 311.1644, ∆M −0.7 ppm; [M +
Na]+ calcd for C20H22O3Na+, 333.1461, found 333.1460, ∆M +0.3 ppm.
Compound 17a: ECD (c 5.9 mM, CH3CN) λmax (∆ε) 194 (−3.1), 211 (+11.1), 279 (−0.7), 308 (+1.1),
323 (+0.9) nm.
Compound 17b: ECD (c 6.4 mM, CH3CN) λmax (∆ε) 194 (+3.5), 211 (−10.9), 280 (+1.2), 309 (−1.3),
325 (−0.7) nm.
Compound 18: white, amorphous powder; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 208, 218, 292–321 nm; 1H and 13C NMR data, see Tables 2
and 3; (+)HRESIMS m/z [M + H]+ calcd for C30H29O6+, 485.1959, found 485.1943, ∆M +3.2 ppm; [M +
Na]+ calcd for C30H28O6Na+, 507.1778, found 507.1760, ∆M +3.6 ppm.
Compound 18a: ECD (c 1.7 mM, CH3CN) λmax (∆ε) 198 (+11.7), 212 (−54.0), 275 (−5.7), 308
(+10.3) nm.
Compound 18b: ECD (c 2.0 mM, CH3CN) λmax (∆ε) 199 (−7.5), 212 (+35.9), 275 (+5.5), 308
(−9.6) nm.
Compound 19: Colourless needle crystals (CD3OD); insufficient material available for optical
rotation; HPLC-UV (MeOH in H2O + 0.1% FA) λmax 206, 221, 277–291 nm; 1H and 13C NMR data,
see Tables 2 and 3; (+)HRESIMS m/z [M + H]+ calcd for C30H29O6+, 485.1959, found 485.1943, ∆M
+3.2 ppm; [M + Na]+ calcd for C30H28O6Na+, 507.1778, found 507.1760, ∆M +3.6 ppm.
Compound 19a: ECD (c 2.0 mM, CH3CN) λmax (∆ε) 190 (−29.5), 202 (−10.7), 216 (−19.7), 233
(+16.3), 249 (+2.1), 266 (+6.0), 290 (−8.6), 310 (+7.4) nm.
Compound 19b: ECD (c 2.0 mM, CH3CN) λmax (∆ε) 190 (+28.1), 202 (+12.9), 216 (+20.0), 232
(−14.9), 249 (−2.1), 266 (−6.0), 292 (+8.4), 310 (−7.2) nm.
Compound 23: yellowish, amorphous solid; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 208, 219, 296-326 nm; 1H and 13C NMR data, see Tables 2
and 3; (+)HRESIMS m/z [M + H]+ calcd for C20H23O3+, 311.1642, found 311.1641, ∆M +0.2 ppm; [M +
Na]+ calcd for C20H22O3Na+, 333.1461, found 333.1446, ∆M +4.5 ppm.
Compound 23a: ECD (c 3.2 mM, CH3CN) λmax (∆ε) 190 (−5.5), 213 (+6.1), 244 (+1.7), 261 (−0.3),
311 (−0.7) nm.
Compound 23b: ECD (c 2.4 mM, CH3CN) λmax (∆ε) 190 (+5.7), 213 (−5.1), 244 (−1.1), 258 (+0.4),
311 (+0.7) nm.
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Compound 24: yellowish, amorphous solid; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 0.1% FA) λmax 201, 225, 278–292 nm; 1H and 13C NMR data, see Tables 2
and 3; (+)HRESIMS m/z [M + H]+ calcd for C30H29O6+, 485.1959, found 485.1943, ∆M +3.2 ppm; [M +
Na]+ calcd for C30H28O6Na+, 507.1778, found 507.1760, ∆M +3.6 ppm.
Compound 24a: ECD (c 2.0 mM, CH3CN) λmax (∆ε) 190 (−25.0), 204 (+14.7), 216 (+24.3), 233
(−29.3), 260 (−0.6), 280 (+9.5), 306 (−31.1) nm.
Compound 24b: ECD (c 3.1 mM, CH3CN) λmax (∆ε) 190 (+26.7), 204 (−13.5), 216 (−23.4), 233
(+30.1), 260 (+1.4), 280 (−8.5), 306 (+32.0) nm.
Compound 25: yellowish, amorphous solid; insufficient material available for optical rotation;
HPLC-UV (MeOH in H2O + 01% FA) λmax 206, 222, 278–292 nm; 1H and 13C NMR data, see Tables 2
and 3; (+)HRESIMS m/z [M + H]+ calcd for C30H29O6+, 485.1959, found 485.1943, ∆M +3.2 ppm; [M +
Na]+ calcd for C30H28O6Na+, 507.1778, found 507.1760, ∆M +3.6 ppm.
Compound 25a: ECD (c 2.0 mM, CH3CN) λmax (∆ε) 190 (+6.4), 203 (+17.6), 212 (−18.1), 223 (+4.7),
238 (+3.5), 274 (−6.0), 307 (+4.6) nm.
Compound 25b: ECD (c 1.8 mM, CH3CN) λmax (∆ε) 190 (−6.0), 203 (−16.9), 212 (+18.3), 223 (−4.3),
238 (−3.1), 274 (+6.1), 307 (−4.4) nm.
3.7. ECD Data Acquisition and Calculations
ECD spectra were recorded on a J-1500 spectrometer (JASCO, Tokyo, Japan) equipped with a
1 mm path length cuvette. Calculation of ECD spectra was performed essentially as suggested for
good computational practice for assignment of absolute configuration by comparison of calculated
and experimental ECD spectra [46]. Thus, after establishment of the relative configuration by
NMR spectroscopy, conformational searches for 6a, 11b, 14b, 15b, 17a, 18b, 19a, 23b, 24a and
25b were performed with MacroModel in Maestro ver. 11.8 (Schrödinger, New York, NY, USA)
in the gas phase (energy window 21 kJ/mol) using Molecular Merck force field static (MMFFs).
This yielded one conformer for 15b, 17a, 18b, 19a, 24a and 25b; two conformers for 11b, 14b and
23b; and ten conformers for compound 6a (Boltzmann′s population fraction weight threshold >0.5%,
see supplementary information). The geometries of the selected conformers were optimized using
density functional theory (DFT) with B3LYP/6-31G(d,p) level of theory in CH3CN [47,48] adopting
to the polarizable continuum model (PCM) to describe the solvent [49,50]. Subsequently, the ECD
spectra of each conformer were calculated with time-dependent density functional theory (TDDFT)
at the B3LYP/6-311G(d,p) level in CH3CN solution as described by PCM [51]. 20 excited states of
each conformer were included for 6a, 11b, 14b, 15b, 17a and 23b, 30 excited states of each conformer
were included for 18b, 24a and 25b, and 40 excited states of each conformer were included for 19a.
All DFT and TDDFT calculations were performed using the Gaussian16 package [52] (Gaussian, Inc.,
Wallingford, CT, USA) with Gaussian′s default setup for the PCM calculations. The final calculated
ECD spectrum of each compound was generated by averaging the individual spectra of its low-energy
conformer according to their Boltzmann distribution using SpecDis23 ver. 1.71 (Berlin, Germany) [53]
adopting the following bandwidths and UV shifts: 6a: 0.18 eV, −4 nm, 11b: 0.30 eV, −1 nm, 14b: 0.20 eV,
−4 nm, 15b: 0.30 eV, 4 nm, 17a: 0.30 eV, −3 nm, 18b: 0.28 eV, 2 nm, 19a: 0.20 eV, 2 nm, 23b: 0.20 eV,
−1 nm, 24a: 0.28 eV, 8 nm, and 25b: 0.20 eV, 1 nm. Calculated and experimental ECD spectra were
compared quantitatively by calculation of the enantiomeric similarity index (∆ESI) [53] using built-in
routines in SpecDisc. Geometry optimization and calculation of ECD spectra were also attempted with
CAM-B3LYP in combination with e.g., the 6-311G(d,p) and/or aug-cc-pvdz basis sets, but resulted in
less reliable data.
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3.8. NMR Experiments
NMR experiments were recorded with standard pulse programs on 600 MHz Avance III
spectrometers (Bruker BioSpin, Karlsruhe, Germany) equipped with 1.7-mm TCI and 5-mm DCH
cryoprobes using 1.7- or 2.5-mm NMR tubes, respectively. Samples were recorded in methanol-d4
at 300 K, and 1H and 13C NMR chemical shifts were referenced to the residual solvent signal of
methanol-d4 (δ 3.31 and δ 49.0, respectively). 1H NMR spectra were recorded using 30◦ pulses and
64 k data points. For the 2D NMR experiments, phase-sensitive DQF-COSY and ROESY spectra
were recorded using a gradient-based pulse sequence with 12 ppm spectral width and 2k × 512 data
points (processed with forward linear prediction to 1k data points in F1); a multiplicity-edited HSQC
spectrum was acquired with the following parameters: 1J C,H = 145 Hz, spectral width 12 ppm for
1H and 170 ppm for 13C, 1730 × 256 data points (processed with both forward linear prediction and
zero filling to 1k data points in F1), and 1.0 s relaxation delay; HMBC experiment was optimized for nJ
C,H = 8.0 Hz (long range), 1J C,H min = 125 Hz, 1J C,H max = 160 Hz and acquired using a spectral width
of 12 ppm for 1H and 240 ppm for 13C, 2k × 256 data points (processed with forward linear prediction
to 512 data points and zero filling to 1k data points in F1), and a 1.0 s relaxation delay.
3.9. X-ray Crystallographic Analysis of 19
Single crystals suitable for X-ray diffraction studies were grown in deuterated methanol. A single
crystal was mounted and immersed in a stream of nitrogen gas [T = 123(2) K]. Data were collected,
using graphite-monochromated CuKα radiation (λ = 1.54178 Å) on a Bruker D8 Venture diffractometer.
Data collection and cell refinement were performed using the Bruker Apex2 Suite software (Bruker AXS,
Madison, WI, USA). Data reduction using SAINT ver. 8.37A (Bruker AXS) and multi-scan correction
for absorption using Bruker/Siemens Area Detector Absorption Correction program SADABS-2016-2
(Bruker/Siemens Area Detector Absorption Correction program) were performed within the Apex2 Suite.
The crystal data, data collection and the refinement data are given in Supplementary Material Table S16.
Positions of all non-hydrogen atoms were found by direct methods (SHELXS97) [54]. Full-matrix
least-squares refinements (SHELXL-2018/3) [55] were performed on F2, minimizing Σw(Fo2 – kFc2)2,
with anisotropic displacement parameters of the non-hydrogen atoms. The positions of hydrogen
atoms were located in subsequent difference electron density maps and were included in calculated
position with fixed isotropic displacement parameters (Uiso = 1.2Ueq for CH, and Uiso = 1.5Ueq for
CH3). Refinement (space group C2/c: 374 parameters, 5191 unique reflections) converged at RF = 0.0357,
wRF2 = 0.0868 [4591 reflections with Fo > 4σ(Fo); w−1 = (σ2(Fo2) + (0.0381P)2 + 5.584P), where P = (Fo2 +
2Fc2)/3; S = 1.037]. The residual electron density varied between -0.33 and 0.35 e Å−3. Complex scattering
factors for neutral atoms were taken from International Tables for Crystallography as incorporated in
SHELXL [55,56]. Fractional atomic coordinates, a list of anisotropic displacement parameters, and a
complete list of geometrical data has been deposited in the Cambridge Crystallographic Data Centre
(CCDC 1982785). Copies of the data can be obtained, free of charge, on application to the director, CCDC,
12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 1223 336 033 or e-mail: deposit@ccdc.cam.ac.uk).
4. Conclusions
To summarize, 13 new prenyl- and geranyl-substituted coumarin derivatives were isolated and
identified in the ethyl acetate extract of G. piloselloides, guided by combined use of HPLC-PDA-HRMS
and dual high-resolution PTP1B/α-glucosidase inhibition profiling for pinpointing new natural
products as inhibitors of PTP1B and/or α-glucosidase. Compound 6 with a furan-oxepane 5/7 ring
system represents a novel class of geranyl-substituted coumarin, and compounds 19 and 24 also
represent a novel class of dimeric natural products consisting of both coumarin and chromone moieties.
Interestingly, chiral resolution showed that ten of the compounds were racemic mixtures, and the
absolute configuration of the separated enantiomers 6a/b, 11a/b, 14a/b, 15a/b, 17a/b, 18a/b, 19a/b, 23a/b,
24a/b and 25a/b were determined by comparison of their experimental and calculated ECD spectra
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as well as by single X-ray crystallography of one of the isolated dimeric coumarin derivatives (19).
This study demonstrates the advantage of the combined use of dual high-resolution inhibition profiling
and hyphenated LC-PDA-HRMS for pinpointing new compounds with potential as dual inhibitors,
and the microplate-based inhibition profiling can be extended to include multiple pharmacological
targets. Further improvement in the preparative-scale chiral separation of enantiomers is however
needed to allow isolation of enantiomerically pure material for further characterization of the mode
of inhibition.
Supplementary Materials: The following are available online, HRMS and 1D data of known compounds,
chromatograms from chiral separations, ECD spectra, details of ECD calculation, X-ray crystallographic analysis
of 19, and 1D and 2D NMR spectra of new compounds identified in this study.
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